World's first once-weekly insulin for type 2 diabetes arrives in Israel

Israel has introduced Awiqli, the world's first once-weekly insulin injection for type 2 diabetes, developed by Novo Nordisk. This treatment significantly reduces the burden of daily injections for patients, though it is currently available only through private purchase.
Why it matters
This medical advancement represents a major shift in diabetes management, potentially improving quality of life and treatment adherence for hundreds of thousands of patients.
Good news for patients with type 2 diabetes: Awiqli, the world's first insulin administered in a single weekly injection, is arriving in Israel. Developed by pharmaceutical company Novo Nordisk, the treatment reduces the number of insulin injections from 365 a year to just 52. Initially, it will be available through private purchase, at a price of 280 to 527 shekels per package, depending on the dosage. Each package can last up to 12 weeks. Awiqli was approved in the European Union in 2024 and in the United States in March 2026, and has also been registered in Israel. In September, the U.S. Food and Drug Administration (FDA) approved another weekly insulin, Eli Lilly's Onswik, although it remains unclear when that treatment will become available in Israel. Insulin is a hormone that helps transport sugar from the bloodstream into the body's cells, where it is used for energy.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in